RecruitingNCT07330830

Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population (AdipoDROMExpo)

Study of PNPLA3 Genetic Polymorphisms in Patients With Non-Alcoholic Fatty Liver Disease in an Ultramarine Population

Sponsor

Centre Hospitalier Universitaire de la Guadeloupe

Enrollment

600 participants

Start Date

Nov 26, 2025

Study Type

OBSERVATIONAL

Conditions

MASLD/MASH (Metabolic Dysfunction-Associated Steatotic Liver Disease / Metabolic Dysfunction-Associated Steatohepatitis)

Summary

Metabolic Dysfunction Associated Liver Disease (MASLD) is associated with metabolic syndrome, and PNPLA3 variants are known to be implicated in intrahepatic lipid accumulation and linked to lipotoxicity. Analysis of PNPLA3 polymorphisms in an overseas territories population of MASLD would be interesting to describe their profile susceptibility to develop Metabolic dysfunction associated steatohepatitis (MASH).

Eligibility

Min Age: 18 Years

Inclusion Criteria4

Adult patients (≥18 years old) seen in consultation or hospitalized in the Hepato-Gastroenterology Departments of the University Hospitals of Guadeloupe, French Guiana, and Réunion Island, with a diagnosis of MASLD.
MASLD is defined as evidence of hepatic steatosis associated with overweight/obesity, type 2 diabetes, or metabolic syndrome according to ATP III (2005) criteria.
Patients affiliated with, or beneficiaries of, a social security scheme.
Free, informed, and written consent obtained from the participant and signed by both the participant and the investigator (no later than the day of inclusion and prior to any procedure required by the study).

Exclusion Criteria11

Patients under 18 years of age.
Patients unable to provide informed consent; so-called vulnerable populations (individuals under guardianship, judicial protection, etc.).
Presence of another cause of chronic liver disease, including:
Viral hepatitis (B, C, or E)
Primary biliary cholangitis or primary sclerosing cholangitis
Autoimmune hepatitis
Wilson's disease
Hemochromatosis
Alpha-1 antitrypsin deficiency
Alcoholic liver disease, or daily alcohol consumption \>30 g/day for men or \>20 g/day for women
Pregnant women.

Print for Your Doctor

Interested in this trial?

Get notified about updates and connect with the research team.

Locations(3)

Centre Hospitalier Universitaire de la Guyane

Cayenne, French Guiana

CHU de la Guadeloupe

Pointe-à-Pitre, Guadeloupe

Centre Hospitalier Universitaire de la Réunion

Saint-Denis, Reunion

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07330830

Related Trials